Provided by Tiger Trade Technology Pte. Ltd.

Viridian Therapeutics, Inc.

24.29
-0.2100-0.86%
Pre-market: 24.300.0100+0.04%06:47 EDT
Volume:906.30K
Turnover:22.04M
Market Cap:2.75B
PE:-7.02
High:24.75
Open:24.65
Low:24.07
Close:24.50
52wk High:34.29
52wk Low:13.18
Shares:113.29M
Float Shares:108.00M
Volume Ratio:0.57
T/O Rate:0.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4579
EPS(LYR):-3.3245
ROE:-65.74%
ROA:-30.16%
PB:4.88
PE(LYR):-7.31

Loading ...

Fairmount Healthcare Fund II buys 1,176,470 Viridian shares for $20 million

Reuters
·
May 14

Viridian prices USD 250 million 1.75% convertible notes due 2032

Reuters
·
May 12

BUZZ-U.S. STOCKS ON THE MOVE-Krispy Kreme, Tesla, Axon Enterprise

Reuters
·
May 08

BUZZ-Viridian Therapeutics drops on increased stock, convertible bond offerings

Reuters
·
May 07

Viridian prices upsized USD 225 million 1.75% convertible senior notes due 2032

Reuters
·
May 07

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock With Aggregate Gross Proceeds of $350.0 Million

THOMSON REUTERS
·
May 07

Stock Track | Viridian Therapeutics Plunges 6.67% in Pre-Market Amid Mounting Losses and Profitability Concerns

Stock Track
·
May 06

Viridian Therapeutics launches USD 150 million convertible senior notes due 2032 offering

Reuters
·
May 06

BUZZ-U.S. STOCKS ON THE MOVE-TransDigm, Rhythm Pharmaceuticals, Intel

Reuters
·
May 06

Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Viridian Therapeutics (VRDN)

TIPRANKS
·
May 06

Analysts Are Bullish on These Healthcare Stocks: Ufp Technologies (UFPT), Viridian Therapeutics (VRDN)

TIPRANKS
·
May 05

Viridian Therapeutics Up Over 24%, on Pace for Largest Percent Increase Since September 2024 -- Data Talk

Dow Jones
·
May 05

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Henry Schein (HSIC), Viridian Therapeutics (VRDN) and Q32 Bio (QTTB)

TIPRANKS
·
May 05

Viridian Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 05

Viridian eye disease drug surpasses expectations in late-stage trial; shares soar

Reuters
·
May 05

Viridian Therapeutics Shares Jump 26% Premarket After Co's Eye Disease Drug Meets Main of a Late-Stage Trial in Chronic Patients

THOMSON REUTERS
·
May 05

Viridian announces REVEAL-2 phase 3 study met primary endpoint

TIPRANKS
·
May 05

Viridian Q1 FY26 net loss widens to $104.9 million; revenue rises to $141,000

Reuters
·
May 05

Viridian says elegrobart meets Phase 3 endpoint in chronic thyroid eye disease trial

Reuters
·
May 05

BRIEF-Viridian Therapeutics Q1 Revenue USD 6 Thousand Vs. IBES Estimate USD 27.5 Thousand

Reuters
·
May 05